Drug-Induced Liver Injury Caused by Kratom Use as an Alternative Pain Treatment Amid an Ongoing Opioid Epidemic

Caroline Stokes Osborne, MD¹, Amanda N. Overstreet, DO¹, Don C. Rockey, MD¹, and Andrew D. Schreiner, MD, MSCR¹

Abstract
Kratom (Mitragyna speciosa) is a prevalent medicinal plant used mainly for the stimulant and analgesic properties provided through multiple alkaloid compounds. Over the past decade, use of kratom has increased despite the limited knowledge of toxicities and adverse side effects. With the current opioid epidemic, both patients and providers are seeking alternative methods to treat both addiction and pain control, and kratom as an alternative means of treatment has increasingly entered the mainstream. In this article, we present the clinical course of a 47-year-old male who developed fatigue, pruritus, and abnormal liver tests (with a mixed hepatocellular/cholestatic pattern) approximately 21 days after beginning kratom. After extensive evaluation including a negligible alcohol history, negative hepatitis serologies, and inconclusive imaging, the patient was diagnosed with drug-induced liver injury (DILI) caused by kratom. Nine months after his liver tests returned to normal, he took kratom again, and after a latency of 2 days, he developed fatigue, pruritus, and loss of appetite along with abnormal liver tests (with the same biochemical profile as previously), consistent with a positive rechallenge. We believe, through the use of the Roussel-Uclaf Causality Assessment Method and expert opinion, that this is a highly likely or definite example of kratom-induced DILI. With the gaining popularity of this drug, it appears that DILI may be an important complication of kratom for providers to recognize.

Keywords
kratom, DILI, acute liver injury, opioid epidemic

Case Description
A 47-year-old man presented to our university-based internal medicine clinic with complaints of dark urine, pruritus, subjective fevers, and fatigue for several days duration. He described subjective fevers with objective measurements ranging from 100°F to 101°F for 2 days with subsequent symptoms of dysuria, urinary frequency, urinary urgency, and darkening of his urine despite large volumes of oral intake. The patient developed generalized malaise, a reduction in appetite, and diffuse pruritus without an associated rash or change in skin color. He reported one episode of nonbloody, nonbilious emesis. He endorsed sick contacts noting his 2 children suffered upper respiratory infection symptoms of cough, rhinorrhea, and sore throat. He denied any recent travel, hospitalizations, or antibiotic use. He took acetaminophen for symptom control but restricted its use to the recommended 3000 mg per day limit. He denied any new or over-the-counter medications including herbal supplements. His previous medical history was notable for obesity (body mass index of 32.68 kg/m²), hypertension, prediabetes (previous A1C 6.2%), anxiety, major depressive disorder, and untreated hypertriglyceridemia. His current medications entailed valsartan, metoprolol tartrate, escitalopram, clonazepam, and fexofenadine. His vitals on presentation included a temperature of 36.7°C, heart rate of 53 beats/min, blood pressure of 127/84 mm Hg, and oxygen saturation of 96% on room air. His physical examination revealed nonicteric sclera and sublingual jaundice. He possessed no lymphadenopathy or hepatomegaly. Initial laboratory testing included a

¹Medical University of South Carolina, Charleston, SC, USA

Received October 4, 2018. Revised October 12, 2018. Accepted October 28, 2018.

Corresponding Author:
Caroline Stokes Osborne, MD, Department of Medicine, Medical University of South Carolina, 135 Rutledge Avenue, Charleston, SC 29425, USA.
Email: osborn@musc.edu
of care urinalysis notable for the presence of urobilinogen and no leukocyte esterase or nitrites. Additional blood work revealed an elevated total bilirubin of 5.8 mg/dL with a direct bilirubin of 4.3 mg/dL, elevated aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) of 108 U/L, 114 U/L, and 170 U/L, respectively, and an albumin of 3.5 g/dL. His serum creatinine was 1.1 mg/dL with a blood urea nitrogen level of 15 mg/dL. A urinalysis with microscopy noted 30 mg/dL protein, moderate bilirubin, 4.0 mg/dL urobilinogen, and 2 red blood cells per high-power field. The patient was contacted via phone with the laboratory results with an emphasis on the hyperbilirubinemia and elevated aminotransferases. Further history was solicited, and the patient reported a trip to Seattle 3 weeks prior to presentation where he received kratom from a friend. The patient reported that he ingested kratom capsules in an effort to manage his low back pain. Initially, he admitted to only using kratom once. On further questioning, he reported using the substance on multiple occasions, but not daily, at the time of presentation. He again denied alcohol use. His medical stability with normal mental mention and robust support system allowed for further evaluation in the outpatient setting.

Further testing revealed a normal prothrombin time and international normalized ratio. Repeat liver tests revealed an uptrend in total bilirubin to 6.1 mg/dL, with a direct bilirubin of 5.1 mg/dL, elevated AST, ALT, and ALP of 114 U/L, 324 U/L, and 148 U/L, respectively, and an albumin 3.5 g/dL. A right upper quadrant ultrasound identified hepatic steatosis without cholelithiasis, cholecystitis, or duct dilation. Additional laboratory tests included an undetectable acetaminophen level, negative Epstein-Barr virus polymerase chain reaction, negative acute hepatitis panel (testing for viral hepatitis A, B, and C), normal α-1 antitrypsin level, and negative antinuclear antibody. He also had a normal thyroid-stimulating hormone of 2.168 U/mL and ceruloplasmin level of 35 mg/dL. The ferritin was elevated at 818 ng/mL with otherwise normal iron studies. Notably, his cytomegalovirus (CMV) IgM antibody index returned positive at 1.7. Laboratory values both 1 week and 2 weeks post index showed improving, but persistent, abnormalities (Table 1). The patient remained out of the hospital during the entire clinical course without complications.

Nine months after the resolution of his symptoms and liver test abnormalities, the patient again presented with 2 days of fatigue, loss of appetite, and intense pruritus without rash. A laboratory evaluation revealed a total bilirubin of 3.2 mg/dL, an AST of 185 IU/L, an ALT of 566 IU/L, and an ALP of 211 U/L. After intense questioning, the patient reluctantly admitted to using kratom again, this time in a powder form. This was his first use of kratom since his initial presentation. Given the similar symptoms, biochemical profile, and shortened latency, this constituted a positive rechallenge and further validated the diagnosis of drug-induced liver injury (DILI) caused by kratom. Fortunately, he suffered no impairment of his liver’s synthetic function, and his liver chemistries trended toward normal 3 weeks following rechallenge.

### Discussion

This case provides a clear example of DILI caused by kratom. Initially, this patient’s presentation entailed a clinical scenario of acute liver injury with a number of potentially contributing factors, including nonalcoholic fatty liver disease (NAFLD), CMV hepatitis, and kratom use. However,

| Days From First Abnormal | ALT (U/L) | ALP (U/L) | Bilirubin (mg/dL) | AST (U/L) | Event |
|-------------------------|-----------|-----------|------------------|-----------|-------|
| −21                     |           |           |                  |           | Agent started |
| −3                      |           |           |                  |           | Symptoms started |
| 0                       | 265       | 170       | 5.8              | 108       | Sought care, negative HAV, HBV, HCV |
| 2                       | 324       | 148       | 6.1              | 114       | Normal PT/INR/PTT; US scan of liver with steatosis |
| 8                       | 149       | 127       | 3                | 36        | Asymptomatic |
| 16                      | 135       | 144       | 1.3              | 51        | Asymptomatic |
| 58                      | 60        | 73        | 0.6              | 25        | Asymptomatic |

Abbreviations: ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; HAV, hepatitis A virus; HBV, hepatitis B virus; HCV, hepatitis C virus; PT, prothrombin time; INR, international normalized ratio; PTT, partial thromboplastin time; US, ultrasound.
Table 2. Cases of DILI Caused by Kratom.

| Presentation | Our Case | LiverTox #6972a | LiverTox #8332a | Dorman et al |
|--------------|----------|----------------|----------------|-------------|
| Kratom exposure | | | | |
| Duration of use | Unknown | Initial | Initial | Initial |
| Latency | 18 days | 24 days | 23 days | 26 days |
| Initial liver tests | | | | |
| Bilirubin (mg/dL) | 5.8 | 22.4 | 2.1 (mixed) | 0.52 (cholestatic) |
| AST (U/L) | 108 | 272 | 428 | 270 |
| ALT (U/L) | 265 | 126 | 218 | 79 |
| ALP (U/L) | 170 | 79 | 270 | 790 |
| R ratio | | | | |
| Initial | 5.2 (HC) | 2.1 (mixed) | 5.0 (mixed) | 0.24 (cholestatic) |
| Peak | 7.3 (HC) | 4.9 (mixed) | | |

Abbreviations: DILI, drug-induced liver injury; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; HC, hepatocellular.

Rapid and comprehensive history taking plays a central role in evaluating abnormal liver tests. Clinicians need to assess patients for critical exposures including alcohol and medication use and pay particular attention to the use of over-the-counter medications and herbal supplements in order to swiftly identify potential cases of DILI. DILI is hepatotoxicity caused by the ingestion of prescription medications, over-the-counter products, and herbal and dietary supplements. Herbal and dietary supplements have especially garnered recent attention given their immense popularity, limited Food and Drug Administration oversight, and linkage to hepatotoxicity. A report from the Drug-Induced Liver Injury Network (DILIN) attributed nearly 15% of DILI cases to herbal and dietary supplements, particularly those used for body building and weight loss. Diagnosing DILI relies on excluding other potential causes of liver toxicity using clinical, biochemical, and pathologic information obtained via history taking, physical examination, and diagnostic testing. However, given the subjectivity of this information, achieving an accurate diagnosis can prove difficult. In order to provide objective assessment, clinicians assess the pattern of liver injury in suspected DILI using R ratios. Using values obtained at the onset of suspected DILI and calculated by the equation $R = (\text{ALT/ULN [upper limit of normal]} ÷ (\text{ALP/ULN})$, R ratios help categorize liver injury into hepatocellular ($R < 2$), mixed ($2 \leq R \leq 5$), and cholestatic ($R > 5$) patterns. Additionally, clinicians can incorporate this score into the Roussel-Uclaf Causality Assessment Method (RUCAM) instrument, a validated tool for DILI diagnosis. The RUCAM tool applies historical and objective information to provide a clinical likelihood of DILI. However, this tool relies heavily on information regarding the timing between use of the offending agent and the onset of liver injury. In this case, the patient’s history of kratom ingestion evolved over time, highlighting both potential difficulties in obtaining exposure histories and the need to pursue the history meticulously and relentlessly.
Our case shares similar clinical and laboratory features reported in previously reported kratom-induced DILI cases (Table 2). The chief complaints of fatigue, nausea, pruritus, and dark urine in our patient with a latency of 21 days after the ingestion of kratom resembles previous cases.\(^\text{16-18}\) Objectively, our patient first presented with an initial \(R\) ratio 5.2 suggestive of a hepatocellular pattern of injury with marked hyperbilirubinemia (5.8 mg/dL, 4.8 times the upper limit of normal). The \(R\) ratio peaked at 7.3 and the total bilirubin at 6.1 mg/dL. Using the RUCAM instrument, patient’s data in the initial presentation resulted in a score of +6, suggesting a “probable” diagnosis of DILI.\(^\text{13}\) This cumulative score included points for time to onset (5-90 days, +2), course (ALT decreasing >50% within 30 days, +2), exclusion of other causes of liver injury (all save CMV, +1), and previous information on hepatotoxicity (LiverTox reports, +1). When the patient returned with symptoms and an \(R\) ratio of 9 after another instance of kratom use, the likelihood of DILI significantly heightened. Using the RUCAM again, the positive rechallenge with a short latency and doubling of ALT (an in this case) in response to the agent alone adds a +3 to the score, moving the total to a +9, which equates to a “high probability” or “definite” case of DILI caused by kratom. Between our case and previous reports, kratom appears to be able to cause any biochemical injury pattern ranging from cholestatic to hepatocellular (Table 2).

Multiple clinically significant confounders apply to our case, as are often found in most DILI cases.\(^\text{19}\) As previously noted, the patient likely had NAFLD at baseline, which could potentiate liver injury of any variety. Testing also revealed a positive CMV IgM, providing a diagnostic alternative despite the test’s limitations in specificity and the incomplete clinical picture. Additionally, there may be contributions from other pharmacologic exposures in this case. Our patient admitted to taking acetaminophen at the start of his symptoms but had undetectable levels found on the day of presentation. The patient also took a long-term selective serotonin reuptake inhibitor. Given the serotonergic-related activity, the capacity to inhibit cytochrome P450 enzymes, and the liver metabolism of both agents, the potential for drug-herb interactions in this case loom large.\(^\text{20}\)

The United States is in the midst of an opioid epidemic. As the government, medical societies, and individual practitioners address this public health concern, other legal means of analgesia are increasing in popularity.\(^\text{21-23}\) Hundreds of online retailers throughout the United States and Europe advertise and sell countless herbal products for stimulant and analgesic purposes. One of these herbal products frequently advertised as an opium substitute is kratom (\(Mitragyna speciosa\)).\(^\text{24}\) \(Mitragyna speciosa\) is a native plant to Southeast Asia and originally used by manual laborers as a means to combat fatigue and enhance work productivity due to its stimulant and analgesic properties.\(^\text{25}\) The opioid-like properties stem from multiple alkaloid compounds, namely, mitragynine and 7-hydroxymitragynine, which bind to the \(mu\), \(kappa\), and \(delta\) receptors.\(^\text{26}\) The pharmacology of kratom is complex as it also interacts within the serotonergic and adrenergic pathways.\(^\text{25}\) Kratom provides a stimulant effect at low doses (1-5 g) and opioid-like effects at high doses (5-15 g). Kratom leaves are consumed through several means: brewing as a tea, smoked, chewed, or processed into a form of an ingestible capsule.\(^\text{25,26}\) The mechanism of ingestion plays a critical role in evaluating the potential harm of this compound, as a recent study found significantly higher concentrations of active metabolites in commercially available kratom supplements compared with raw, unprocessed \(Mitragyna\) leaves.\(^\text{27}\) The use of concomitant medications is also of concern, as \(Mitragyna\) may inhibit cytochrome P450 enzymes and potentiate harmful herb-drug interactions (ie, serotonin syndrome).\(^\text{20}\) Symptoms observed during withdrawal from kratom resemble those of opioid withdrawal with rhinorrhea, myalgias, dysphoria, decrease in appetite, and diarrhea.\(^\text{21,25}\) Nonetheless, due to its analgesic properties, companies advertise and patients consume kratom either as a “natural” means of chronic pain control or opioid withdrawal symptom management.\(^\text{21,25}\) Many uncertainties surround kratom with regard to its safety profile, side effects, potential drug interactions, and overdose threshold.\(^\text{21-22}\) A Centers for Disease Control and Prevention report from July 2016 noted a 10-fold increase in reports to poison centers around the United States regarding the ingestion of kratom.\(^\text{28}\) Despite the growing popularity and concomitant safety concern of kratom, literature regarding the safety profile and side effects of kratom remains limited.

**Conclusion**

As the opioid epidemic in the United States continues, patients may turn to unconventional means of pain control. Herbal supplements, such as kratom, are gaining in popularity in part due to ease of access but also due to the presentation of kratom as a safe, natural way to self-taper and control withdrawal symptoms. Patients may be turning to kratom to manage symptoms of withdrawal when they lack access to medication-assisted treatment for opioid use disorder. Unfortunately, the safety of kratom is not confirmed, and the literature regarding its safety profile and side effects is limited. As patients and providers work together in a patient-centered paradigm to curb opioid use and find alternative adjuvants for pain control, herbal supplements with opioid properties like kratom will have to be considered. Providers must diligently inquire about herbas and supplements now when taking a pain history. Additionally, providers must seek to educate patients regarding the lack of kratom’s safety profile, lack of known overdose threshold, and lack oversite over the manufacturing of kratom in order to continue an open dialogue between patient and provider.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding support was provided by the NIDDK 1K23DK118200-01 (Principal Investigator: Andrew D. Schreiner).

Ethics Approval
Our institution does not require ethical approval for reporting individual cases or case series.

Informed Consent
Verbal informed consent was obtained from the patient(s) for their anonymized information to be published in this article.

References
1. Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
2. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313:2263-2273.
3. Fromenty B. Drug-induced liver injury in obesity. J Hepatol. 2013;58:824-826.
4. Boyle M, Masson S, Anstee QM. The bidirectional impacts of alcohol consumption and the metabolic syndrome: cofactors for progressive fatty liver disease. J Hepatol. 2018;68:251-267.
5. Jensen KO, Angst E, Hetzer FH, Gingert C. Acute cytomegalovirus hepatitis in an immunocompetent host as a reason for upper right abdominal pain. Case Rep Gastroenterol. 2016;10:36-43.
6. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev. 2002;15:680-697.
7. Ross SA, Novak Z, Pasi S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets. 2011;11:466-474.
8. Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf Causality Assessment Method. Hepatology. 2010;51:2117-2126.
9. Fontana RJ, Watkins PB, Bonkovsky HL, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32:55-68.
10. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbs and dietary supplements in the US Drug-Induced Liver Injury Network. Hepatology. 2014;60:1399-1408.
11. Hayashi PH, Barnhart HX, Fontana RJ, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int. 2015;35:1623-1632.
12. Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11:272-276.
13. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331-1336.
14. Haque T, Satasomi E, Hayashi PH. Drug-induced liver injury: pattern recognition and future directions. Gastroenterology. 2016;150:27-36.
15. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. Summary of case 6972. https://livertox.niddk.nih.gov/Home/ReferenceCases/kratom/6972. Accessed January 10, 2019.
16. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. Summary of case 8332. https://livertox.niddk.nih.gov/Home/ReferenceCases/kratom/8332. Accessed January 10, 2019.
17. Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: a case report. Hepatology. 2015;61:1086-1087.
18. Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. J Community Hosp Intern Med Perspect. 2018;8:107-110.
19. Teschke R, Danan G. Systematic review: drug induced liver injury: alternative causes in case series as confounding variables. Br J Clin Pharmacol. 2018;84:1467-1477.
20. Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharmacognosy Res. 2013;5:241-246.
21. Chang-Chien GC, Odonkor CA, Amorapanth P. Is kratom the new “legal high” on the block? The case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician. 2017;20:E195-E198.
22. Hillebrand J, Olszewski D, Sedefov R. Legal highs on the Internet. Subst Use Misuse. 2010;45:330-340.
23. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragyna speciosa korth). Addiction. 2008;103:1048-1050.
24. Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (Mitragynina speciosa korth). J Neurol Neurosurg Psychiatry. 2008;103:1048-1050.
25. Cinosi E, Martinotti G, Simonato P, et al. Following “the roots” from a traditional use to increase work and productivity in the Internet. Subst Use Misuse. 2015;61:27-36.
26. Osborne et al. Criteria of drug-induced liver injuries. Report of an international consensus meeting. J Hepatol. 1990;11:272-276.
27. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993;46:1331-1336.
28. Haque T, Satasomi E, Hayashi PH. Drug-induced liver injury: pattern recognition and future directions. Gastroenterology. 2016;150:27-36.
29. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. Summary of case 6972. https://livertox.niddk.nih.gov/Home/ReferenceCases/kratom/6972. Accessed January 10, 2019.
30. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox. Summary of case 8332. https://livertox.niddk.nih.gov/Home/ReferenceCases/kratom/8332. Accessed January 10, 2019.
31. Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: a case report. Hepatology. 2015;61:1086-1087.
32. Tayabali K, Bolzon C, Foster P, Patel J, Kalim MO. Kratom: a dangerous player in the opioid crisis. J Community Hosp Intern Med Perspect. 2018;8:107-110.
33. Teschke R, Danan G. Systematic review: drug induced liver injury: alternative causes in case series as confounding variables. Br J Clin Pharmacol. 2018;84:1467-1477.
34. Hanapi NA, Ismail S, Mansor SM. Inhibitory effect of mitragynine on human cytochrome P450 enzyme activities. Pharmacognosy Res. 2013;5:241-246.
35. Chang-Chien GC, Odonkor CA, Amorapanth P. Is kratom the new “legal high” on the block? The case of an emerging opioid receptor agonist with substance abuse potential. Pain Physician. 2017;20:E195-E198.
36. Hillebrand J, Olszewski D, Sedefov R. Legal highs on the Internet. Subst Use Misuse. 2010;45:330-340.
37. Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self-treatment of opioid withdrawal using kratom (Mitragyna speciosa korth). Addiction. 2008;103:1048-1050.
38. Nelsen JL, Lapoint J, Hodgman MJ, Aldous KM. Seizure and coma following kratom (Mitragynina speciosa korth). J Neurol Neurosurg Psychiatry. 2008;103:1048-1050.
39. Cinosi E, Martinotti G, Simonato P, et al. Following “the roots” from a traditional use to increase work and productivity in the Internet. Subst Use Misuse. 2015;61:27-36.
40. Osborne et al. Criteria of drug-induced liver injuries. Report of an international consensus meeting. J Hepatol. 1990;11:272-276.